Mircera 30 _g/0.3 m_, 50 _g/0.3 m_, 75 _g/0.3 m_, 100 _g/0.3 m_, 120 _g/0.3 m_, 150 _g/0.3 m_, 200 _g/0.3 m_, 250 _g/0.3 m_, 360 _g/0.6 m_ Injection
PDF Leaflet Revision Date: 07 December 2022
Clinical Summary
Quick overview from the medicine insert
Indication
Treatment of anaemia associated with chronic kidney disease (CKD) in adults.
Dosage (summary)
Starting dose: 1.2 u03bcg/kg SC once monthly or 0.6 u03bcg/kg SC/IV every two weeks.
Special Populations
- Elderly
- Hepatic impairment
Pregnancy & Breastfeeding
Contraindicated in pregnancy and lactation; safety not established.
Contraindications
- Uncontrolled hypertension
- Hypersensitivity
- Pregnancy
- Lactation
Common side effects
- Hypertension
- Headache
Counselling Points
- Monitor haemoglobin levels regularly
- Do not mix with other products
- Report any signs of severe anaemia or hypertension
Serious warnings
- Risk of Pure Red Cell Aplasia (PRCA)
- Monitor blood pressure
- Increased risk of serious cardiovascular events
Important Disclaimer
The Mircera 30 _g/0.3 m_, 50 _g/0.3 m_, 75 _g/0.3 m_, 100 _g/0.3 m_, 120 _g/0.3 m_, 150 _g/0.3 m_, 200 _g/0.3 m_, 250 _g/0.3 m_, 360 _g/0.6 m_ Injection professional information leaflet below is the property of Roche Products and is provided on Medinsert exactly as issued, with no.. alterations or editorial changes. We make every effort to keep content current by updating documents as soon as new versions become available. Medinsert serves as a trusted access point for healthcare professionals, but does not replace official sources or clinical judgement. For more details, please read our full disclaimer. read more>>
Healthcare Professionals Only
This content is for registered healthcare professionals
Sign in or create a free account to read the full package insert.
Free for HPCSA-registered professionals. Powered by Medinsert.
